Author of

• 12046

  +

  MO14 - Mesothelioma II - Surgery and Multimodality (ID 121)

  • Event: WCLC 2013
  • Type: Mini Oral Abstract Session
  • Track: Mesothelioma
  • Presentations: 1
  • Moderators:E. Lim, B. McCaughan
  • Coordinates: 10/29/2013, 10:30 - 12:00, Bayside Gallery B, Level 1

  • 12051

    +

    MO14.05 - Intracavitary Cisplatin-Fibrin Chemotherapy after Resection for Malignant Pleural Mesothelioma Patients (INFLuenCe-Meso) - preliminary results (ID 2683)

    10:50 - 10:55  |  Author(s): C. Bommeli
    • Abstract
    • Presentation
    • Slides

    Background
    Local mesothelioma recurrence remains a challenge even after multimodal therapy. Intracavitary chemotherapy is a promising approach to improve local tumor control. In preclinical studies we observed improved pharmacokinetic characteristics when cisplatin was loaded to a fibrin carrier and applied to the chest wall after surgery while effectiveness remained the same compared to cisplatin applied as a solution. We will present the first results of a phase I –dose-escalation-clinical study.

    Methods
    Since 11/2012 3 patients were included in the study. Cisplatin-fibrin was applied after pleurectomy/decortication (P/D) to the chest wall in a concentration of 11 mg/m[2] BSA. Blood samples were taken at several time points after the application (2, 6, 10, 24, 48 and 120 hours) to assess serum cisplatin levels and to test toxicity in the early phase until 14 days postoperatively. The concentration of total platinum was quantified by means of inductively coupled plasma sector field mass spectrometric detection. Adverse events were graded according to the CTCAE.

    Results
    Between November 2012 and March 2013 three patients (2x epithelioid, 1x biphasic) in stage II, III and stage IV were included and received P/D plus Cisplatin-Fibrin in a concentration of 11 mg/m[2]. The maximum concentration of cisplatin in the serum was below 0.3 µg/g at 2 h after application and continued to decrease over a period of 5 days (see image 1). No severe adverse events were observed. The adverse events documented were not related to cisplatin (table 1):

    Diagnosis / symptoms	CTC AE grading	Number of patients	Related to Cisplatin
    Fatigue	Grade II	2	possible
    Anemia	Grade III	2	unlikely
    Nausea / vomiting	Grade I	1	possible
    Increased kreatinin & urea levels	Grade II	1	possible
    Increased CK levels	Grade IV	1	unlikely
    Increased level of transaminases	Grade III	1	unlikely
    Urinary retention	Grade II	1	unlikely
    Hypotension	Grade II	1	unlikely
    Pneumothorax	Grade II	1	unlikely

    Figure 1

    Conclusion
    Our preliminary results show, that cisplatin-fibrin application to the chest wall and the lung surface after P/D is safe on a dose level of 11mg/m2 BSA. As no treatment related mortality and no drug related toxicity was observed we escalate the dosage to 22 mg/m2 BSA, further results including chest wall concentrations of cisplatin will be available in October.

    Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.